Loading...
NPI 1093792350 · Rochester, MN · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Mayo Collaborative Services, Inc is a clinical medical laboratory provider located in Rochester, Minnesota. This profile covers 425 Medicare and 344 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Mayo Collaborative Services, Inc |
| Address | 200 1st St Sw |
| City | Rochester |
| State | MN |
| ZIP | 55905 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 28, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $39.2M |
| Medicare | $6.5M |
MAYO COLLABORATIVE SERVICES, INC shows a Medicaid-dominant payer mix with lifetime Medicaid revenue of $39.2M versus total Medicare revenue of $6.5M, indicating Medicaid is the primary revenue source for this entity. The scale of Medicaid receipts compared with Medicare suggests the operation functions largely as a high-volume inpatient/outpatient reference lab for state-covered populations rather than being driven by Medicare fee-for-service volumes alone.
Medicaid revenue is highly concentrated: the top three Medicaid codes account for 67.9% of this provider’s Medicaid revenue, led by U0003 at $16.9M (54.4% of Medicaid revenue) and U0005 at $2.8M (8.9% of Medicaid revenue), followed by G0482 at $1.5M (4.7% of Medicaid revenue). U0003 and U0005 both rank #1 in-state and are labeled extreme outlier, far above typical state volume for these codes, which confirms that high-throughput SARS-CoV-2 testing has driven the majority of Medicaid receipts.
The provider’s Medicare revenue is also concentrated in molecular and genomic diagnostics: the top three Medicare codes account for 48.3% of Medicare revenue and are 81528, 81455, and 81450. These codes correspond to stool-based DNA cancer screening and multi-gene genomic panels, indicating Medicare revenue is driven by advanced molecular oncology and cancer-screening assays rather than routine chemistry or primary care services.
Code mix and descriptions point to a hybrid business model combining very high-throughput infectious disease testing with specialized molecular oncology, immunogenetics, and pathology services. High-volume infectious codes on Medicaid (U0003, U0005, 87631) alongside Medicare-dominant codes such as 81455, 81450, 81528, and HLA testing 81376 imply infrastructure that supports automation for mass testing plus technical capacity for complex sequencing and cytogenetic workflows.
On national Medicare competitive standing, the provider is a clear leader for several specialized assays and pathology services: 81376 ranks #1 of 24 nationally and is an extreme outlier, 88350 ranks #3 of 652 (extreme outlier), and 88341 ranks #40 of 10274 (extreme outlier). At the same time, the highest-revenue Medicare code 81528 ranks as typical versus national peers (rank #2 of 4; 67th percentile), showing a mix of leadership in niche tests but typical volume for some high-revenue molecular panels.
Statewide on Medicaid, the provider is dominant for pandemic-era and other infectious testing: U0003 and U0005 both rank #1 in-state and are labeled extreme outlier, and additional codes such as 87798, 87631, 87902, and 87522 also show #1 in-state or extreme outlier status. This pattern indicates market leadership in Minnesota for SARS-CoV-2 and multiplex respiratory/viral testing, as well as certain virology and molecular assays.
The facility’s concentration in a few very large codes creates sensitivity to changes in demand for those services: U0003 alone represents $16.9M and 54.4% of Medicaid revenue, and the precomputed top-three shares (67.9% Medicaid, 48.3% Medicare) underline that a small set of tests drives most revenue. While that concentration underpins current scale, it also means revenue streams could shift materially if public health testing needs or reimbursement for those high-volume codes change.
MAYO COLLABORATIVE SERVICES, INC has an established presence with NPI enumeration dated 2005-12-28 (~21 years ago), which supports the profile of a long-standing reference laboratory. Combined lifetime revenues of $6.5M Medicare and $39.2M Medicaid, plus extreme outlier rankings on multiple in-state and national codes, paint the picture of a mature, large-scale diagnostic operation with both broad high-volume testing capacity and specialized molecular/clinical laboratory expertise.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
425 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 81528 | The lab analyst uses a stool sample and performs the technical lab tests for a fecal hemoglobin test and for real time amplification of 10 DNA markers. The lab analyst then carries out an algorithmic… | 1,860 | $500 | $929.6K |
| 81455 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as tumor tissue or bone marrow, for DNA and possibly RNA alterations in 51 or more genes known to… | 200 | $2,860 | $569.3K |
| 81450 | The lab analyst performs a genomic sequence analysis panel to evaluate the patient specimen, such as blood or bone marrow, for DNA and possibly RNA alterations in five to 50 genes known to impact… | 650 | $740 | $480.6K |
| 81206 | The lab analyst performs the technical lab test to evaluate the major breakpoint gene sequence BCR/ALB1 that occurs on chromosome 22 due to translocation, which involves breakage and reforming of an… | 1,520 | $160 | $244.4K |
| 88350 | The analyst performs an immunofluorescent study using a single antibody stain procedure to detect autoimmune disease or an infectious organism in a tissue or cellular sample. Code +88350 describes… | 3,370 | $50 | $165.2K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 820 | $200 | $160.7K |
| 81376 | The lab analyst performs the technical lab test for low or intermediate resolution assessment of human leukocyte antigen genes, called HLA, for one Class II locus using molecular techniques. | 1,140 | $120 | $137.3K |
| 88341 | The lab analyst applies an additional single antibody stain on a slide or slides prepared from the same patient specimen as the initial antibody stain, such as tumor tissue. Then a qualified… | 3,780 | $30 | $117.2K |
| 88237 | The lab analyst performs a procedure to grow a culture of cells from bone marrow or blood in a neoplastic disorder. | 790 | $140 | $110.8K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 5,390 | $20 | $102.4K |
Showing 1–10 of 425
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 425 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
425 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 81528 | 1 | 10 | 1,460 | $500 | $727.3K |
| 81455 | 1 | 10 | 120 | $2,840 | $346.3K |
| 81450 | 1 | 10 | 370 | $740 | $276.5K |
| 88185 | 2 | 10 | 7,580 | $20 | $144.7K |
| 81206 | 1 | 10 | 290 | $160 | $98K |
| 81376 | 1 | 10 | 800 | $120 | $95.6K |
| 0077U | 2 | 10 | 910 | $40 | $95.1K |
| 81268 | 1 | 10 | 310 | $260 | $77.9K |
| 86833 | 7 | 10 | 30 | $310 | $68.2K |
| 86832 | 7 | 10 | 30 | $310 | $68K |
Showing 1–10 of 425
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
344 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 276,890 | $60 | $16.9M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 162,290 | $20 | $2.8M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 9,940 | $150 | $1.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 19,630 | $70 | $1.4M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 23,660 | $50 | $1.1M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 9,360 | $90 | $795.3K |
| 87631 | The lab analyst performs the technical steps to detect three to five types or subtypes of pathogens, such as adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus,… | 6,430 | $110 | $733.2K |
| 87902 | The lab analyst performs the technical lab test to analyze the specific genotype by nucleic acid of a specimen containing hepatitis C virus. | 3,430 | $210 | $723.7K |
| 83655 | The lab analyst performs a test to measure the amount of lead in the patient specimen. A typical aim of the test is to check for lead exposure. | 45,840 | $20 | $687.6K |
| 87522 | A lab tests a patient’s specimen to measure the amount of hepatitis C virus present. This may be referred to as viral load. | 12,950 | $40 | $479K |
Showing 1–10 of 344
How this provider's Medicaid billing volume and revenue compare to other Minnesota providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Minnesota median
344 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 10 | 2,200 | $120 | $1.3M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 30 | 340 | $60 | $890.4K |
| 87902 | The lab analyst performs the technical lab test to analyze the specific genotype by nucleic acid of a specimen containing hepatitis C virus. | 1 | 10 | 3,430 | $210 | $723.8K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 9 | 100 | 510 | $40 | $560.8K |
| 81511 | The lab analyst performs the technical lab tests for four analytes, AFP, uE3, hCG, and DIA, and carries out an algorithmic analysis using patient data and the lab test results to report a patient… | 1 | 10 | 2,690 | $110 | $307.4K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 270 | 550 | $70 | $254.7K |
| 88305 | The physician, typically a pathologist, performs a level IV examination of a surgical pathology specimen. The examination includes accessioning the specimen into the lab, which involves formally… | 42 | 120 | 650 | $50 | $225.2K |
| 81229 | The lab analyst performs the technical lab test using comparative genomic hybridization (CGH) microarray, also referred to as chromosomal microarray (CMA) or molecular karyotype performed by… | 1 | 10 | 580 | $320 | $185.1K |
| 88185 | The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with… | 1 | 10 | 1,230 | $130 | $164.6K |
| 82330 | The lab analyst measures this ionized form of calcium primarily on serum, blood, or a capillary sample. Providers use ionized calcium testing extensively during major surgeries where the importance… | 3 | 10 | 910 | $10 | $127.6K |
Showing 1–10 of 344
Other providers in the same ZIP code as Mayo Collaborative Services, Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Mayo Clinic | MN | Multi-Specialty Clinic/Center | $0 | $74.3M |
| Mayo Clinic | MN | Clinical Medical Laboratory | $12.2M | $15.2M |
| Mayo Clinic | MN | Multi-Specialty Clinic/Center | $0 | $10.9M |
| Mayo Foundation For Medical Education & Research | MN | Durable Medical Equipment & Medical Supplies | $9.3K | $2.8M |
| Vidhu Kaushik | MN | Clinical Pathology/Laboratory Medicine Physician | $59.6K | $1.9M |
| Roberto Leon Ferre | MN | Medical Oncology Physician | $1.3M | $0 |
| Peter Noseworthy | MN | Cardiovascular Disease Physician | $1.1M | $0 |
| Daniel Childs | MN | Medical Oncology Physician | $1.1M | $0 |
| Robert Jacobson | MN | Pediatrics Physician | $975.6K | $0 |
| Brittany Siontis | MN | Medical Oncology Physician | $960.6K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.